ReviewJournal of labelled compounds & radiopharmaceuticals2014
Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals.
Review in Journal of labelled compounds & radiopharmaceuticals, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 107 citations in OpenAlex.
- Design, Synthesis, and Preclinical Evaluation of Novel Dimeric RM2-Based Radioligands for GRPR-Targeted Breast Cancer Imaging.Molecular pharmaceutics · 2026Article
- [Npj imaging · 2026Article
- On-Resin DIAMSAR-Conjugated CD38-Targeted Peptides and Their Inverso and Dimeric-Inverso Analogs for PET Imaging of Multiple Myeloma.Bioconjugate chemistry · 2026Article
- Radiocopper in BCMA-targeted immunotheranostics of myeloma.Theranostics · 2026Article
- eTFC-01: a dual-labeled chelate-bridged tracer for SSTR2-positive tumors.EJNMMI radiopharmacy and chemistry · 2024Article
- Radiomics and Artificial Intelligence in Radiotheranostics: A Review of Applications for Radioligands Targeting Somatostatin Receptors and Prostate-Specific Membrane Antigens.Diagnostics (Basel, Switzerland) · 2024Review
- Methods for the Production of Radiolabeled Bioagents for ImmunoPET.Methods in molecular biology (Clifton, N.J.) · 2024Review
- Coordination Chemistry of Sulfur-Containing Bifunctional Chelators: TowardInorganic chemistry · 2023Article
- Pentadentate and Hexadentate Pyridinophane Ligands Support Reversible Cu(II)/Cu(I) Redox Couples.Inorganics · 2023Article
- Radionuclide Cisternography with [Pharmaceuticals (Basel, Switzerland) · 2023Article
- Peptide-based positron emission tomography probes: current strategies for synthesis and radiolabelling.RSC medicinal chemistry · 2023Review
- Increasing Reaction Rates of Water-Soluble Porphyrins forMolecules (Basel, Switzerland) · 2023Article
- Synthesis and In Vitro Comparison of DOTA, NODAGA and 15-5 Macrocycles as Chelators for theMolecules (Basel, Switzerland) · 2022Article
- Article
- Chelation of Theranostic Copper Radioisotopes with S-Rich Macrocycles: From Radiolabelling of Copper-64 to In Vivo Investigation.Molecules (Basel, Switzerland) · 2022Article
- Development and Functional Characterization of a Versatile Radio-/Immunotheranostic Tool for Prostate Cancer Management.Cancers · 2022Article
- Article
- A Prospective Study Assessing the Post-Prostatectomy Detection Rate of a Presumed Local Failure at mpMR with EitherCancers · 2021Article
- Copper Coordination Chemistry of Sulfur Pendant Cyclen Derivatives: An Attempt to Hinder the Reductive-Induced Demetalation inInorganic chemistry · 2021Article
- Proof-of-Concept Study of the NOTI Chelating Platform: Preclinical Evaluation ofMolecular imaging and biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The development of chelating agents for copper radionuclides in positron emission tomography radiopharmaceuticals has been a highly active and important area of study in recent years. The rapid evolution of chelators has resulted in highly specific copper chelators that can be readily conjugated to biomolecules and efficiently radiolabeled to form stable complexes in vivo. Chelators are not only designed for conjugation to monovalent biomolecules but also for incorporation into multivalent targeting ligands such as theranostic nanoparticles. These advancements have strengthened the role of copper radionuclides in the fields of nuclear medicine and molecular imaging. This review emphasizes developments of new copper chelators that have most greatly advanced the field of copper-based radiopharmaceuticals over the past 5 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.